4TEEDE HJ, MEYER C, NORMAN RJ. Insulin-sensitisers in the treatment of polycystic ovary syndrome[J]. Expert Opin Pharmacother, 2005, 6: 2419-2427.
5Dunaif A.Hyperandrogenic anovulation(PCOS):a uniquic disorder of insulin action assoeia-ted with an increased risk of non-insulindependent diabetes mellitus[J].Am J Med,1995,98(Suppl):33-39.
6The Eshre Capri Workshop.Female infertility:treatment options for complicated cases[J].Hum Reprod,1997,12:1191-1196.
7Mitwallym FM,Casper R F.Aromatase inhibition reduces the dose of gonadotrop in required for controlled ovarian hyperstimulation[J].J Soe Gynecol lnvestig,2004,11:406-415.
8Cortinez A,D E Carvalho I,Vantman D.Hormonal profile and endometrial morphology inletrozole controlled ovarian hyperstimulation in ovulatory infertile patients[J].Fertil Steril,2005,83:110-115.
9[1]Diamanti KE,Kouli CR,Bergiele AT,et al.A Survey of the polycystic ovary syndrome in the Greek island of Lesbox hormonal and metabolic profile[J].J Clin Endocrinol Metab.1999,84:4006-24011.
10[2]The Rotterdam ESHRE/ASRM-Sponsored PCOS Workshop Group.Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycvstic ovary syndrome.Fertil Steril.2004,81(1):19-25.
6Liu W H,Kaur M. Inverse PCR-based RFLP scanning identifies low-level mutation signatures in colon cells and tumors[J]. Cancer Res, 2004,64(8) : 2544-2551.
7Azziz R, Woods K S, Reyna R, et al. The prevalence and features of the polyoystic ovary syndrome in an unselected population[J]. Clin Endocrinol Metab, 2004, 89:2745-2749.
8ildiz B O, Knochenhauer E S, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome[J]. Clin Endocrinol Metab, 2008,93(1):162-168.
9The Rotterdam ESHRE / ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consesus on diagnostic crtiteria and Iongterm health risks related to polycystic ovary syndrome (PCOS) [J].Hum Reprod, 2004,19:41-47.
10Trujillo M E, Scherer P E. Adipose tissue-derivedfactors: impact on health and disease[J].Endocr Rev, 2006, 27:762-778.
